2. UroToday Home
  3. Video Lectures

Precision Medicine in Prostate Cancer

Combining Lutetium-PSMA with Hormonal Therapy Enhances Prostate Cancer Treatment - Louise Emmett
November 8, 2024
Details
Epigenetic Profiling Identifies Biomarkers Predicting Resistance to AR-Targeted Therapy in mCRPC - Wilbert Zwart
November 2, 2024
Details
INSPIRE Trial Investigates Immunotherapy for Molecularly Selected Advanced Prostate Cancer - Niven Mehra
October 7, 2024
Details
Novel Epigenomic Liquid Biopsy Detects PSMA Expression in Prostate Cancer - Jacob Berchuck
October 2, 2024
Details
First-in-Class AR Degrader Shows Promise in Castration-Resistant Prostate Cancer - Dana Rathkopf
October 1, 2024
Details
TALAPRO-2 Analysis: Talazoparib Enzalutamide Combo in Pretreated mCRPC - Neeraj Agarwal
September 30, 2024
Details
CONTACT-02 Trial Results: Cabozantinib Plus Atezolizumab for mCRPC - Neeraj Agarwal
September 30, 2024
Details
Exploring Actinium-225: Transforming Cancer Treatment with Targeted Radiopharmaceuticals - John Valliant
September 3, 2024
Details
Overcoming Hormone Resistance: ARV-766 in Advanced Prostate Cancer - Daniel Petrylak
August 6, 2024
Details
Antibody Drug Conjugate FOR46: Targeting CD46 in mCRPC in Phase 1b Trial - Nonna Shakhnazaryan
August 5, 2024
Details
Copper-67 (Cu-67 or 67Cu) in Cancer Therapy: Current Developments and Future Potential - Alan Taylor
July 31, 2024
Details
Advancing Radiopharmaceuticals: From Lead-212 to Pre-Targeting Strategies - Michael Schultz
July 31, 2024
Details
Radiopharmaceuticals and Combination Approaches in Advancing the Prostate Cancer Treatment Landscape - Philip Kantoff
July 30, 2024
Details
Cell Surface Targets in mCRPC: Expression Landscape and Therapeutic Potential - Michael Haffner
July 22, 2024
Details
2024 NCCN Guidelines Update: Metastatic Castration-Resistant Prostate Cancer Treatment - Rashid Sayyid & Zachary Klaassen
July 10, 2024
Details
PSCA CAR T-Cell Therapy for Metastatic CRPC: Phase 1 Trial Results - Tanya Dorff
June 21, 2024
Details
Targeting EZH2 in Prostate Cancer: The Role of Mevrometostat in Preventing Neuroendocrine Differentiation - Michael Schweizer
June 18, 2024
Details
Tarlatamab Shows Encouraging Activity in Phase 1 Trial in DLL3-Positive Neuroendocrine Prostate Cancer - Rahul Aggarwal
June 17, 2024
Details
ctDNA Fraction Predicts Response to Lutetium PSMA in TheraP Trial for mCRPC - Edmond Kwan
June 17, 2024
Details
Integrating Genetic Variants and Clinical Factors for Improved Prostate Cancer Prognostication - Susan Halabi
June 11, 2024
Details
Olaparib plus Abiraterone Versus Placebo plus Abiraterone in Metastatic Castration-Resistant Prostate Cancer (PROpel): Final Prespecified Overall Survival Results of a Randomised, Double-Blind, Phase 3 Trial - Fred Saad
June 10, 2024
Details
UCHL1: A Potential Biomarker and Therapeutic Target for Neuroendocrine Prostate Cancer - Tanya Stoyanova
June 4, 2024
Details
The Use of PARP Inhibitors in mCRPC with BRCA1/2 Alterations - Joaquin Mateo
May 22, 2024
Details
The Adrenal Permissive HSD3B1 Allele: A Decade-Long Journey from Initial Discovery to Proven Clinical Significance in Prostate Cancer - Nima Sharifi
April 25, 2024
Details
NePtune Trial: Evaluating Neoadjuvant PARP Inhibition in BRCA-Mutated Prostate Cancer - Rana McKay
March 26, 2024
Details
Alpha vs Beta Emitters in Prostate Cancer Radiopharmaceuticals: Energy, Range, and Cytotoxicity - Alan Bryce
March 5, 2024
Details
BRCAAWAY Trial: Impact of Abiraterone and Olaparib Combination in Prostate Cancer - Maha Hussain
February 22, 2024
Details
BRCAAway Trial: Where Combination Treatment Improve Patient Outcomes in mCRPC - Daniel George
February 6, 2024
Details
Novel Biomarker Analysis Reveals SPOP Gene Mutation Unlocks Sensitivity to PARP Inhibitor Treatment in Metastatic Castration-Resistant Prostate Cancer - Emmanuel Antonarakis & Jacob Orme
December 12, 2023
Details
Combination Therapy Jolts 'Exhausted' Immune Cells Awake to Attack Tumors in Patients with Metastatic Castration-Sensitive Prostate Cancer - Jessica Hawley & Aleksandar Obradovic
November 29, 2023
Details
Parsing the Evidence from the EMBARK Trial on a Promising New Drug Regimen in High-Risk Non-Metastatic Hormone-Sensitive Prostate Cancer - Matthew Cooperberg
November 21, 2023
Details
AMG 509's Potential in Prostate Cancer Therapy - Michael Morris
November 17, 2023
Details
Genetic Testing Reveals Treatment Opportunity and Disparity in Advanced Prostate Cancer - Colin Pritchard
November 17, 2023
Details
Influencing Best Practices for Genomic and Germline Testing in Urology - Abhishek Srivastava
October 6, 2023
Details
Loss of SYNCRIP Unleashes APOBEC-Driven Mutagenesis, Tumor Heterogeneity and AR-Targeted Therapy Resistance in Prostate Cancer - Ping Mu
August 14, 2023
Details
Understanding the Underutilization of Germline Genetic Testing in Prostate Cancer - Sarah Young & David Wise
August 14, 2023
Details
Decoding Exceptional Responses: The National Cancer Institute's Unique Prostate Cancer Study - Fatima Karzai & Rana McKay
June 13, 2023
Details
Exploring the Clinical Trial Landscape for Metastatic Castration-Resistant Prostate Cancer: Insights on Genetic Testing, Radiopharmaceuticals, and Promising Trials - Elena Castro
April 25, 2023
Details
Challenges, Controversies, and Opportunities of PARP Inhibitor Combinations with Androgen Receptor Signaling Inhibitors - Kim Chi
April 12, 2023
Details
Interim Overall Survival Analysis of TRITON3: Rucaparib vs Physician's Choice of Therapy in mCRPC with Homologous Recombination Deficiency - Alan Bryce
April 12, 2023
Details
Overview of the Decipher® Genomic Classifier
March 9, 2023
Details
Final Overall Survival Results from the PROpel Phase 3 Trial in First-line Therapy for mCRPC - Fred Saad
March 3, 2023
Details
Clinically Relevant Biomarkers in Castration-Resistant Prostate Cancer - Noel Clarke
January 24, 2023
Details
Rucaparib for Patients with Metastatic Castration-Resistant Prostate Cancer in the TRITON3 Trial – Oliver Sartor
January 23, 2023
Details
From Blood to Diagnosis: the Role of ctDNA in Prostate Cancer Treatment - Alexander Wyatt
January 11, 2023
Details
Advances in Liquid Biopsies for Guiding Cancer Therapy - Jeffrey Ross
January 10, 2023
Details
Rucaparib Monotherapy Improves Radiographic Progression-Free Survival in Patients With Metastatic Castration-Resistant Prostate Cancer: TRITON3 Trial - Alan Bryce
December 20, 2022
Details
Genetic and Genomic Testing in Prostate Cancer LUGPA 2022 Presentation - Emmanuel Antonarakis
December 15, 2022
Details
rPFS Improvement Regardless of Mutations in Biomarker Subgroups in the Phase III PROpel Trial in First-Line Therapy for Patients with mCRPC - Fred Saad
November 16, 2022
Details
PROCLAIM Study Reveals Impact of Germline Genetic Testing on Prostate Cancer Clinical Decisions - Neal Shore
November 15, 2022
Details
Extending Prostate Genetic Awareness, Navigation and Delivery for Genetic Testing in Males of African American Decent - The EXPAND Network, 2021 PCF-Pfizer Global Health Equity Challenge Award - Veda Giri
October 16, 2022
Details
BRCAAway - a Randomized Phase 2 Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients with mCRPC with DNA Repair Defects - Maha Hussain
August 2, 2022
Details
Integrating 177Lu-PSMA-617 in Clinical Practice - Oliver Sartor
July 4, 2022
Details
Incorporating Molecular Testing into Clinical Practice for Prostate Cancer - Elena Castro & Colin Pritchard
July 4, 2022
Details
Fast Facts: The Importance of Genetic Testing in Prostate Cancer - Brittany Szymaniak
June 23, 2022
Details
Advancing Genetic Testing in Metastatic Prostate Cancer - Brenda Martone
June 23, 2022
Details
The Use of PARP Inhibitors in Castrate-Resistant Prostate Cancer - Elena Castro & Joaquin Mateo
June 19, 2022
Details
Hereditary Cancer Risk Assessment For Prostate Cancer Patients - Neal Shore
April 12, 2022
Details
The Efficacy and Safety of Olaparib + Abiraterone in the First-Line mCRPC Setting PROpel – Fred Saad
March 4, 2022
Details
Association of Inherited Mutations in DNA Repair Genes with Localized Prostate Cancer – Kara Maxwell
February 4, 2022
Details
Genomic Profiling: Germline and Somatic Testing - What You Must Know Today - Emmanuel Antonarakis
December 16, 2021
Details
Should Checkpoint Inhibitors Ever Be Used Outside of a Clinical Trial in Prostate Cancer - James Gulley
March 25, 2021
Details
Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Can Be Preselected to Maximize Benefit of Olaparib - Maha Hussain
October 16, 2020
Details
DNA Repair and PARP Inhibitor Therapy in Prostate Cancer - Veda Giri, Patrick Pilié, and Arpit Rao
July 23, 2020
Details
Integrating Genetics and Genomics into Treatment Decisions for Men with Prostate Cancer - Panagiotis Vlachostergios
July 10, 2020
Details
Personalized Approaches to the Treatment of Prostate Cancer - Kenneth Pienta and James Gulley
July 10, 2020
Details
Implementation of Germline Testing for Prostate Cancer - Veda Giri
July 5, 2020
Details
Clinical Understanding of PARP Inhibitors in Prostate Cancer - Elena Castro, Wassim Abida, and Karen Knudsen
June 2, 2020
Details
PARP Inhibition in Castration-Resistant Prostate Cancer - Daniel Petrylak
May 24, 2020
Details
PARP Inhibitors Changing the Standard of Care for Treatment of Metastatic Prostate Cancer (mCRPC) - The PROfound Study
May 9, 2020
Details
Genetically Informed Treatment for Advanced and Metastatic Prostate Cancer - Alicia Morgans
April 6, 2020
Details
Integrating Germline and Somatic Mutations Tests into Clinical Practice Workflows - Wassim Abida
August 8, 2020
Details
PROfound Study - PARP-inhibitor Olaparib in Advanced Prostate Cancer Patients with Specific Tumor Mutations - Maha Hussain
October 10, 2019
Details
Role of PARP Inhibitors in Prostate Cancer - Evan Yu
February 5, 2019
Details
Results from TRITON2: Treatment of mCRPC with Rucaparib - Alan Bryce
November 29, 2018
Details